A rigorous side-by-side analysis of LactoReborn™ against four leading exosome and extracellular vesicle skincare products — evaluated across biological source, concentration, clinical evidence, regulatory standing, and clinical utility.
For professional reference only. Data compiled from manufacturer disclosures, published literature, and public regulatory records as of Q1 2026. This comparison is intended to inform clinical decision-making and does not constitute medical advice.
The only product using probiotic Lactobacillus-derived EVs — a fundamentally different and scientifically distinct bioactive profile from mammalian or human-origin exosomes.
Combines three distinct EV sources — Lactobacillus, Panax Ginseng callus, and Centella Asiatica callus — for a multi-pathway regenerative effect no single-source competitor can match.
Lactobacillus-derived EV efficacy is supported by multiple independent peer-reviewed publications in ISEV Journals, Nature, PMC, and RSC — not just manufacturer-sponsored studies.
Uniquely pairs EVs with H-PDRN, atelocollagen, and 7 bioactive peptides in a co-delivery system — addressing regeneration, structural support, and pigmentation simultaneously.
Biological Source
Bacterial (Probiotic)
Lactobacillus-derived Extracellular Vesicles — the only product in this class using probiotic-origin EVs, which carry a distinct microbiome-modulating bioactive profile absent from mammalian cell sources.
EV / Exosome Concentration
100 mg EV lyophilizate per vial
Format & Application
Format: Lyophilized EV vial + PDRN/Collagen/Peptide solvent ampoule (2-step system, 5-set box)
Method: Micro-Needle Therapy System (MTS) or needle-free impact technology
Key Active Ingredients
Clinical Evidence
Peer-reviewed scientific literature supports Lactobacillus-derived EV efficacy in skin barrier enhancement, anti-inflammatory activity, wound healing acceleration, and collagen stimulation. Multiple published studies (2020–2025) in ISEV Journals, PMC, Nature, and RSC Biomaterials document the mechanism of action.
Regulatory Status
Professional medical aesthetic product; marketed for topical/MTS use. No FDA drug claims. Manufactured under GMP standards.
Limitations / Notes
Do not use on open wounds, active eczema, or dermatitis. Professional use only.
Biological Source
Human Umbilical Cord
Exosomes derived from Wharton's Jelly (umbilical cord stem cells). Human-origin EVs carry growth factors and miRNAs relevant to skin regeneration.
EV / Exosome Concentration
10 billion or 50 billion exosomes per vial
Format & Application
Format: Glass vial, topical serum
Method: Topical, post-microneedling
Key Active Ingredients
Clinical Evidence
100-person internal microneedling + exosome trial showing improved recovery, texture, firmness, moisture, and radiance. No published peer-reviewed trial data identified at time of research.
Regulatory Status
Registered with the FDA under MoCRA (cosmetic registration). Not FDA-approved as a drug or biologic. Marketed as a topical cosmetic.
Limitations / Notes
No published peer-reviewed clinical data. Not FDA-approved as a drug. Human-origin material requires robust donor screening and sterility validation.
Biological Source
Human Adipose Stem Cells
Exosomes derived from human adipose stromal cells (fat-derived stem cells). Lyophilized to 20 mg per vial with an extensive co-formulation of growth factors, amino acids, and coenzymes.
EV / Exosome Concentration
20 mg lyophilized exosome per vial (particle count not disclosed)
Format & Application
Format: Lyophilized vial (20 mg) + 5 mL diluent
Method: Topical, post-microneedling or RF microneedling
Key Active Ingredients
Clinical Evidence
Published toxicological evaluation (Jan 2021). Active clinical trial on ClinicalTrials.gov (NCT06999408) evaluating safety with TargetCool device. Additional hair density study showing positive results. Evidence base is growing but largely manufacturer-sponsored.
Regulatory Status
Manufactured in an FDA-registered GMP facility. Marketed as a cosmeceutical. Topical exosome use is not regulated or approved by the FDA as a drug.
Limitations / Notes
Particle count not disclosed. Clinical evidence largely manufacturer-sponsored. Topical exosome use not FDA-regulated. Human adipose source requires rigorous donor testing.
Biological Source
Dermal Fibroblast Stem Cells
Polypeptide-enriched conditioned media from dermal fibroblast stem cells. Contains growth factors, matrix proteins, collagen, and enzymes.
EV / Exosome Concentration
Not disclosed
Format & Application
Format: Topical serum/vial (3 mL and 5 mL)
Method: Topical, transdermal; post-laser, microneedling, RF
Key Active Ingredients
Clinical Evidence
Manufacturer before/after photos and marketing claims only. No published peer-reviewed studies or registered clinical trials identified.
Regulatory Status
⚠ FDA Warning Letter issued December 30, 2024 (Case #681586): Products classified as unapproved new drugs AND unlicensed biological products. Company states no FDA evaluation of claims.
Limitations / Notes
FDA Warning Letter (Dec 2024) for unapproved drugs and unlicensed biologics. No peer-reviewed clinical evidence. Concentration not disclosed. Regulatory compliance is a significant concern for practitioners.
Biological Source
Human Umbilical Cord Lining
Exosomes from postnatal human umbilical cord lining stem cells (ULSCs). Uses proprietary StableSome™ Technology for room-temperature stability and 2-year shelf life.
EV / Exosome Concentration
50 billion exosomes per vial (non-diluted)
Format & Application
Format: Vial (room-temperature stable, 2-year shelf life)
Method: Topical only (not injectable)
Key Active Ingredients
Clinical Evidence
References published MSC exosome research (Clinical & Experimental Medicine 2023; DPCJ 2026). No product-specific peer-reviewed clinical trial data identified. StableSome™ Technology is proprietary.
Regulatory Status
Topical cosmetic use only. Not FDA-approved as a drug. Not intended for injection or IV delivery. No FDA drug claims made.
Limitations / Notes
No product-specific peer-reviewed clinical data. Not for injection. Human-origin source requires donor screening. Proprietary StableSome™ Technology is not independently validated.
| Criterion | LactoReborn™Agnes Medical | Age ZeroResilielle | Exosome Regenerative Complex+BENEV | EXO ELIXIR™Evolutionary Biologics | Pure Exosome 50BRejuvion Health |
|---|---|---|---|---|---|
| EV Source | Bacterial (Probiotic) | Human Umbilical Cord | Human Adipose Stem Cells | Dermal Fibroblast Stem Cells | Human Umbilical Cord Lining |
| Concentration | 100 mg EV lyophilizate per vial | 10 billion or 50 billion exosomes per vial | 20 mg lyophilized exosome per vial (particle count not disclosed) | Not disclosed | 50 billion exosomes per vial (non-diluted) |
| Regulatory | Professional / GMP | Cosmetic (MoCRA) | Cosmetic (MoCRA) | ⚠ FDA Warning | Cosmetic (MoCRA) |
| Clinical Evidence | Strong | Moderate | Moderate | Limited | Moderate |
| Delivery Format | Lyophilized EV vial + PDRN/Collagen/Peptide solvent ampoule | Glass vial, topical serum | Lyophilized vial | Topical serum/vial | Vial |
| Application | Micro-Needle Therapy System (MTS) or needle-free impact technology | Topical, post-microneedling | Topical, post-microneedling or RF microneedling | Topical, transdermal; post-laser, microneedling, RF | Topical only (not injectable) |
| Multi-EV Synergy | Yes — 3 EV sources | Single source | Single source | Single source | Single source |
| PDRN Co-Delivery | Yes (H-PDRN) | No | No | No | No |
| Microbiome Safety | Non-human origin — no donor screening required | Human umbilical cord — requires donor screening & sterility validation | Human adipose — requires donor screening & rigorous testing | Human fibroblast — requires donor screening; FDA Warning Letter issued | Human umbilical cord lining — requires donor screening & sterility validation |
Data sourced from manufacturer disclosures, public regulatory records, and published literature as of Q1 2026. For professional reference only.
Contact our team to discuss treatment protocols, training, and how LactoReborn™'s unique probiotic EV science can differentiate your practice.